banter and General Discussion, page-9302

I think you are not far off the mark here Kingtup.....

Really not trying to get ahead of myself, but if one was to assume that MSB is somewhat de-risked based on the FDA notifying the company that the clinical data is sufficient for refiling of the aGVHD BLA, then when I do a comparison of the closing price from the time preceding the second CRL, this appears to be relatively undervalued


Even after I account for dilution, and excluding any potential bump in value based on the announcement that U.S. FDA supports an accelerated approval pathway for rexlemestrocel-L, in patients with end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD), I still believe that fair value might sit north of $1....

Maybe I am missing something here and perhaps the agonising disappointment of the past few years is generating increased investor caution, which is understandable.

Anyway DYOR and this is not intended to be financial advice
GLTAH

V